Obesity Clinical Trial
Official title:
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
The aim of this study is to collect pilot data to compare the effectiveness of treatment with Alpha Lipoic Acid (ALA) for reduction in body weight in 40 obese outpatients with schizophrenia or schizoaffective disorder in an open-label pilot trial. The investigators also plan to test the feasibility of utilizing ALA as a weight loss agent for obese outpatients with schizophrenia or schizoaffective disorder in terms of tolerability, schizophrenia symptoms, cognition and side effects. We have run a total of 12 non-diabetic participants and are now recruiting diabetic patients in hopes of comparing the two groups.
Design: This is a ten week open-label, fixed dose clinical study of alpha lipoic acid (ALA)
for the treatment of antipsychotic weight gain in outpatients with schizophrenia or
schizoaffective disorder.
Study Endpoints: The primary outcome measure is change in body weight from baseline.
Secondary outcome measures are fasting serum glucose, glycosylated hemoglobin, insulin, LDL
cholesterol, triglyceride levels, quality of life (Q-LES-Q), Clinical Global Impression
(CGI) scores and performance on the The Brief Assessment of Cognition in Schizophrenia
neurocognitive battery (BACS). (after preliminary analysis, we have changed the cognitive
assessment to the DSST task only. The investigators are also going to conduct exploratory
analyses of food craving, food preference and food frequency.
Subjects: Subjects will be recruited from the Psychosis Program and clinician referrals from
other teams at the CMHC. Based on our previous weight loss studies the investigators expect
very high enthusiasm from the subjects.
Procedure and assessment schedule: Subjects who meet the inclusion/exclusion criteria will
participate in a multi-step screening process where demographic information will be
gathered, weight and BMI will be measured and fasting blood will be taken, and if you are a
female, a urine sample will be tested for pregnancy. If lab results are adequate, the
subject will continue on to a baseline visit where they will start taking alpha lipoic acid
(ALA) at 600mg three times a day (1800mg total) for a total of ten weeks. At each visit,
weight will be obtained, scheduled blood will be drawn and study ratings will be conducted.
A short visit with the physician every two weeks ensures safety and improves rating
fidelity. Medication compliance will be ensured with pill counts, feedback and encouragement
that is standard for clinical trials with schizophrenia patients. Research scales are
standard schizophrenia and food scales.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |